Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Chase Coleman’s Tiger Global May Lose $14 Million In Cablevision

Cablevision Systems Corp (CVC) slumps today after the company announced yesterday that its COO, Tom Rutledge, would resign from the management team. Rutledge has served in Cablevision for nearly 10 years. He joined the company in 2001, and became COO in 2004.

TIGER GLOBAL MANAGEMENT LLC

CVC closed yesterday at $13.93, and is trading at $11.89 at 12:25PM EST on Friday, down 14.64% or $2.04. Here is a list of hedge funds that may lose millions of dollars due to the decline.

1. Tiger Global Management – Chase Coleman: loses $13.98 million

2. Blue Ridge Capital – John Griffin: loses $10.47 million

3. Omega Advisors – Leon Cooperman: loses $6.50 million

4. Empyrean Capital Partners – Michael A. Price and Amos Meron: loses $4.15 million

5. D. E. Shaw – David E. Shaw: loses $2.52 million

6. Carlson Capital – Clint Carlson: loses $2.35 million

7. Citadel Investment Group – Ken Griffin: loses $2.33 million

8. Wexford Capital – Charles Davidson: loses $2.02 million

9. Highbridge Capital Management – Glenn Russell Dubin: loses $1.87 million

10. SAC Capital Advisors – Steven Cohen: loses $1.71 million

DISCLAIMER: These calculations assume that these hedge funds did not increase or reduce their stock positions in CVC since the end of September. We did not take into account their option positions.

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!